AHCPR Issues Colorectal Cancer Screening Evidence Report

Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

ROCKVILLE, Md--In the first report issued under its new Evidence-based Practice Initiative, the Agency for Health Care Policy and Research (AHCPR) has reaffirmed that early detection and treatment provide the primary means of preventing death from colorectal cancer.

ROCKVILLE, Md--In the first report issued under its new Evidence-basedPractice Initiative, the Agency for Health Care Policy and Research (AHCPR)has reaffirmed that early detection and treatment provide the primary meansof preventing death from colorectal cancer.

Among the conclusions of the report, based on a review of 3,500 citationsfrom the scientific literature (1966 to 1994):

  • Use of fecal occult blood testing followed by diagnostic evaluationand treatment for positive tests can cut colorectal cancer mortality by15% to 33%.
  • A 60-cm flexible sigmoidoscopy identifies nearly all cancers and polypsgreater than 1 cm in diameter and 75% to 80% of small polyps.
  • Sigmoidoscopy screening can reduce colorectal cancer mortality riskby 59% to 80%.
  • Indirect evidence supports the use of double-contrast barium enemain screening for colorectal cancer.
  • While screening colonoscopy offers the potential to both identify andremove cancers and premalignant lesions, no studies completed to date showan associated mortality reduction.
  • Detecting and removing polyps reduces the incidence of colorectal cancer,and removing early cancers lowers mortality. Although both double-contrastbarium enema and colonoscopy detect polyps and tumors, they have not beenstudied as screening tests.

  • © 1997 by PRR, Inc. All rights reserved.
Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content